CING · Cingulate Inc.
AI read · Good for CING
The AI's read
The FDA's earlier letter asked for manufacturing details, not problems with the drug's safety or effectiveness. That gives Cingulate a path to another review, but approval is not assured. The company says its $23.2 million cash balance can fund operations into mid-2027. Its share-sale program could raise more cash, but selling shares may shrink current owners' portions.